Can mild ALT elevation accompany MASLD and hepatic insulin resistance without ruling out advanced liver disease?

Mild ALT elevation is compatible with metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic insulin resistance, but routine “preserved” liver tests do not reliably exclude clinically important fibrosis or compensated cirrhosis.

Clinical and metabolic evidence

• Mild ALT elevation can reflect hepatocyte injury in MASLD, but it neither diagnoses steatosis nor indicates its severity. MASLD requires evidence of steatosis by imaging or biopsy; ALT may also be normal in affected individuals, including in an older-adult population where 88% with NAFLD had normal ALT.
• Human metabolic studies support the association with hepatic insulin resistance. In 1,309 nondiabetic adults, ALT correlated positively with a tracer-derived hepatic insulin-resistance index and inversely with clamp-measured whole-body insulin sensitivity. In 451 nondiabetic Pima participants, higher ALT was associated with greater hepatic glucose output during insulin infusion and later worsening hepatic insulin sensitivity.
• These associations do not make ALT a direct test for liver fat or insulin resistance, and other causes of ALT elevation remain clinically relevant.

Mechanistic context

• Insulin resistance promotes hepatic fatty-acid delivery and de novo lipogenesis, increasing liver fat. Lipotoxic injury can release ALT.
• Higher liver fat is also associated with impaired insulin-mediated suppression of endogenous glucose production, linking steatosis and hepatic insulin resistance without proving a single causal direction.

Fibrosis and practical implications

• Normal AST, bilirubin, and albumin can occur in advanced fibrosis and compensated cirrhosis; they should not be used alone to stage or exclude advanced disease.
• For suspected MASLD, guidelines support fibrosis-specific assessment with FIB-4. A value <1.3 generally indicates low risk; ≥1.3 warrants secondary testing such as elastography or ELF. For adults older than 65, a higher FIB-4 threshold of 2.0 is used.

Bottom line

• Mild ALT elevation can be a metabolic liver-health signal, but preserved AST, bilirubin, and albumin do not establish that advanced liver disease is absent; structured fibrosis risk stratification is needed when clinical risk is present.